Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Urinary Tract Infection

Free Subscription Articles published in Int J Antimicrob Agents Retrieve available abstracts of 31 articles: HTML format

Single Articles

April 2026
1. SINGH N, Srivastav M
   Comment on "ESBL-producing Escherichia coli bacteremic urinary tract infections: clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study".
   Int J Antimicrob Agents. 2026 Apr 20:107820.
   PubMed    
   
   
   
2. YUAN J, Fan D, Wu H, Jia B, et al
   A Multicenter, Randomized, Double-Blind, Imipenem/Cilastatin-Controlled Clinical Study of Cefiderocol for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Pathogens in Chinese Adults.
   Int J Antimicrob Agents. 2026 Apr 15:107812.
   PubMed     Abstract available
   
   
   
3. ZAHAVI I, Kunwar D, Olchowski J, Dallasheh H, et al
   In reply to the Letter to the Editor regarding "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis".
   Int J Antimicrob Agents. 2026 Apr 6:107800.
   PubMed    
   
   
   
4. FALAGAS ME, Romanos LT, Katritsi ED, Tzvetanova ID, et al
   Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies.
   Int J Antimicrob Agents. 2026;67:107723.
   PubMed     Abstract available
   
   
   March 2026
5. KUNWAR D, Zahavi I, Olchowski J, Dallasheh H, et al
   In reply to the Letter to Editor regarding "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis".
   Int J Antimicrob Agents. 2026 Mar 28:107791.
   PubMed    
   
   
   
6. GOMEZ-ZORRILLA S, Rodriguez-Cabale G, Montesinos IL, Alanti SS, et al
   "ESBL-producing Escherichia coli bacteremic urinary tract infections: clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study".
   Int J Antimicrob Agents. 2026 Mar 20:107787.
   PubMed     Abstract available
   
   
   
7. WANG C, Chen J, Yang H, Jiang M, et al
   Comment on'Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis'.
   Int J Antimicrob Agents. 2026 Mar 8:107777.
   PubMed    
   
   
   
8. MAJI C, Srinivasan H, Biradar A, Jauhari R, et al
   Comment on "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis".
   Int J Antimicrob Agents. 2026 Mar 5:107771.
   PubMed    
   
   
   
9. CHEN Q
   Comment on "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis".
   Int J Antimicrob Agents. 2026 Mar 3:107770.
   PubMed    
   
   
   February 2026
10. PIMENTA-DE-SOUZA P, Ramos-Silva A, Sandes V, Portella P, et al
    Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map.
    Int J Antimicrob Agents. 2026;67:107710.
    PubMed     Abstract available
    
    
    
11. LIAO J, Li C, Liu J, Wu W, et al
    Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring.
    Int J Antimicrob Agents. 2026;67:107697.
    PubMed     Abstract available
    
    
    December 2025
12. KUNWAR D, Zahavi I, Olchowski J, Dallasheh H, et al
    Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2025 Dec 22:107696.
    PubMed     Abstract available
    
    
    September 2025
13. COOK JD, Hooey PB, Salazar KC, Clark JR, et al
    Results of TOR001: an open-label single patient study using targeted bacteriophage therapy for the treatment of a chronic urinary tract infection.
    Int J Antimicrob Agents. 2025 Sep 8:107613.
    PubMed     Abstract available
    
    
    
14. BENITEZ-CANO A, Liu X, Xu H, Tang X, et al
    Optimizing Linezolid Dosing for Nosocomial Urinary Tract Infections in Critically Ill Patients with Renal Impairment.
    Int J Antimicrob Agents. 2025 Sep 5:107610.
    PubMed     Abstract available
    
    
    
15. ABRIL D, Solorzano P, Leal AL, Forero-Hurtado D, et al
    Ceftazidime/avibactam resistance in Enterobacter cloacae due to the acquisition of a small pHAD28-like plasmid harbouring bla(KPC-33).
    Int J Antimicrob Agents. 2025;66:107540.
    PubMed     Abstract available
    
    
    September 2024
16. LI P, Xu Q, Ding L, Zhang X, et al
    Q48K mutation in the type IB nitroreductase NrmA is responsible for nitrofurantoin resistance in Enterococcus faecium.
    Int J Antimicrob Agents. 2024;64:107277.
    PubMed     Abstract available
    
    
    
17. RODRIGUEZ-RUIZ JP, Lin Q, Van Heirstraeten L, Lammens C, et al
    Long-term effects of ciprofloxacin treatment on the gastrointestinal and oropharyngeal microbiome are more pronounced after longer antibiotic courses.
    Int J Antimicrob Agents. 2024;64:107259.
    PubMed     Abstract available
    
    
    August 2024
18. YANG W, Chen J, Yang F, Ji P, et al
    Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection.
    Int J Antimicrob Agents. 2024;64:107211.
    PubMed     Abstract available
    
    
    
19. GIMENEZ-PEREZ M, Hernandez S, Padulles A, Boix-Palop L, et al
    Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia.
    Int J Antimicrob Agents. 2024;64:107202.
    PubMed     Abstract available
    
    
    July 2024
20. MESCHIARI M, Asquier-Khati A, Tiseo G, Luque-Paz D, et al
    Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Int J Antimicrob Agents. 2024;64:107186.
    PubMed     Abstract available
    
    
    December 2023
21. SHI H, Zeng L
    Comment on: Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Dec 9:107059.
    PubMed    
    
    
    November 2023
22. KIM C, Choi YH, Choi JY, Choi HJ, et al
    Translation of Machine Learning-Based Prediction Algorithms to Personalised Empiric Antibiotic Selection: A Population-Based Cohort Study.
    Int J Antimicrob Agents. 2023;62:106966.
    PubMed     Abstract available
    
    
    September 2023
23. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    PubMed     Abstract available
    
    
    
24. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    PubMed     Abstract available
    
    
    April 2023
25. HUNG KC, Tsai WW, Hsu CW, Lai CC, et al
    Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Apr 24:106830.
    PubMed     Abstract available
    
    
    
26. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    PubMed     Abstract available
    
    
    March 2023
27. DE OCA JEM, Veve MP, Zervos MJ, Kenney RM, et al
    Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections.
    Int J Antimicrob Agents. 2023 Mar 31:106800.
    PubMed     Abstract available
    
    
    August 2022
28. BELMONT-MONROY L, Ribas-Aparicio RM, Gonzalez-Villalobos E, Perez-Ramos JA, et al
    Molecular typification of Escherichia coli from community-acquired urinary tract infections in Mexico.
    Int J Antimicrob Agents. 2022 Aug 26:106667.
    PubMed     Abstract available
    
    
    April 2022
29. FOSSE PE, Brinkman KM, Brink HM, Conner CE, et al
    Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents.
    Int J Antimicrob Agents. 2022;59:106560.
    PubMed     Abstract available
    
    
    March 2022
30. TUTONE M, Johansen TEB, Cai T, Mushtaq S, et al
    SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Int J Antimicrob Agents. 2022 Mar 17:106574.
    PubMed     Abstract available
    
    
    January 2022
31. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Urinary Tract Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum